CENTER VALLEY, Pa., April 24, 2024 /PRNewswire/ -- Olympus, a global medical technology company committed to making people's lives healthier, safer, and more fulfilling, announced today data showing ...
- Ibezapolstat, the first of a novel class of antibiotics, DNA polymerase IIIC inhibitors, is currently commencing a Phase 2b clinical trial in patients with CDI - Using samples from Phase 1 healthy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback